Each 10 mL of syrup contains Ambroxol Hydrochloride 30 mg, Terbutaline Sulphate IP 2.5 mg, and Guaiphenesin 100 mg.

Salbid Plus Syrup is a combination of Terbutaline Sulphate, Ambroxol Hydrochloride, and Guaiphenesin, formulated to provide effective relief from bronchospasm and productive cough. It combines the bronchodilatory action of Terbutaline with the mucolytic effect of Ambroxol and the expectorant properties of Guaiphenesin to improve airway patency, loosen thick mucus, and facilitate easier expectoration. The formulation helps reduce chest congestion and improves breathing in obstructive airway diseases.

Salbid Plus Syrup is indicated for the symptomatic relief of bronchospasm associated with bronchial asthma and chronic bronchitis. It helps relieve productive cough, chest congestion, wheezing, and breathing difficulty by improving mucus clearance and enhancing airflow through the airways.

Terbutaline is a selective β₂-adrenergic receptor agonist that produces bronchodilation by relaxing bronchial smooth muscles. It also enhances mucociliary clearance, reduces airway edema, and exhibits anti-allergic effects that improve respiratory function. Ambroxol Hydrochloride acts as a mucolytic and expectorant, reducing the viscosity of bronchial secretions and promoting easier mucus clearance. Guaiphenesin is an expectorant that increases the volume and decreases the thickness of respiratory secretions, facilitating productive coughing and relieving chest congestion.

The recommended dosage is 10–20 mL three times daily for adults, 10 mL three times daily for children aged 6–12 years, and 5–10 mL three times daily for children under 6 years, or as directed by the physician.

Salbid Plus Syrup is contraindicated in patients with known hypersensitivity to Terbutaline Sulphate, Ambroxol Hydrochloride, Guaiphenesin, or any component of the formulation. It should not be used in patients with pre-existing ischemic heart disease, significant risk factors for ischemic heart disease, or active gastric ulceration.